BRAF and melanoma: In colon cancer cell lines with or without BRAF-V600E mutation, we found that PLX had no effect on the level of Axin1 nor β-catenin (Fig. 6A), indicating that BRAF-V600E had distinct effect in colon cancer and melanoma cells.